Search company, investor...


Founded Year



Series C - II | Alive

Total Raised




Last Raised

$300M | 2 yrs ago

About Abogen

Abogen is a biopharmaceutical company focusing on the research and development of messenger ribonucleic acid (mRNA) drugs.

Headquarters Location

B2-610, Biomedicine Industrial Park, No. 218, Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu,


Missing: Abogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Abogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Abogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abogen is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,214 items


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Abogen Patents

Abogen has filed 21 patents.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Chromatography
  • Elastomers
patents chart

Application Date

Grant Date


Related Topics




Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors


Application Date


Grant Date



Related Topics

Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors



Latest Abogen News

Genor Partners with Abogen to Develop mRNA Products for Oncology Needs

Jun 24, 2022

publication date: Jun 24, 2022 Shanghai Genor Biopharma has teamed up with Suzhou Abogen Biosciences to develop novel mRNA drugs for oncology indications, merging its biological antibody development platform with Abogen’s mRNA platform. Genor has expertise in identifying bi-specific/multi-specific antibodies for immunoncology. Abogen, which was already an mRNA company before COVID, adapted its technology to develop a mRNA vaccine for the pandemic. Based on the global interest in COVID vaccines, it raised $700 million in a C round one year ago to conduct Phase III trials. Financial details of the agreement were not disclosed. More details.... Stock Symbol: (HK: 6998)

Abogen Frequently Asked Questions (FAQ)

  • When was Abogen founded?

    Abogen was founded in 2003.

  • Where is Abogen's headquarters?

    Abogen's headquarters is located at B2-610, Biomedicine Industrial Park, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou.

  • What is Abogen's latest funding round?

    Abogen's latest funding round is Series C - II.

  • How much did Abogen raise?

    Abogen raised a total of $1.134B.

  • Who are the investors of Abogen?

    Investors of Abogen include 5Y Capital, DNE Capital, SoftBank , Chimera Investments, New Frontier and 37 more.

  • Who are Abogen's competitors?

    Competitors of Abogen include NeoCura.

Compare Abogen to Competitors


NeoCura is a supplier of molecular diagnostic products, covering the entire clinical cycle from the early detection and diagnosis of tumors to precise medical guidance and treatment evaluation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.